2016

    1. Neuropathic Gaucher’s mutations accelerate cofnitive decline in Parkinson’s. Liu G, Boot B, Locascio JJ, Jansen IE, Winder-Rhodes S, Eberly S, Elbaz A, Brice A, Ravina B, Van Hilten JJ, Cormier-Dequaire F, Corvol JC, Barker RA, Heutink P, Marinus J, Williams-Gray CH, Scherzer CR; for the International Genetics of Parkinson Disease Progression (IGPP) Consortium. 2016 Sept 22
      Download Publication
    2. Cognitive decline and quality of life in incident Parkinson’s disease: The role of attention. Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH, Barker RA, Collerton D, Taylor JP, Burn DJ, ICICLE-PD study group. Parkinsonism Relat Disorder. 2016 Jun
      Download Publication
    3. Time on timing: Dissociating premature responding from interval sensitivity in Parkinson’s disease. Zhang J, Nombela C, Wolpe N, Barker RA, Rowe JB. Movement Disorder. 2016 Apr 19
      Download Publication
    4. Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson’s disease with clinical and neuroimaging measures. Ye Z, Rae CL, Nombela C, Ham T, Rittman T, Jones PS, Rodriguez PV, Coyle-Gilchrist I, Regenthal R et al. Human Brain Mapp. 2016 Mar
      Download Publication
    5. Comparative epidemiology of incident Parkinson’s disease in Cambridgeshire, UK. Evans JR, Cummins G, Breen DP, Foltynie T, Mason SL, Brayne CE, Williams-Gray CH, Barker RA. J Neurol Neurosurg Psychiatry. 2016 Jan 22
      Download Publication
    6. Hippocampal dysfunction defines disease onset in Huntington’s disease.Begeti F, Schwab LC, Mason SL, Barker RA. J Neurol Neurosurg Psychiatry. 2016 Feb 01
      Download Publication
    7. Development and external validation of a prognostic model in newly diagnosed disease. Velseboer DC, Die Bie RM, Wieske L, Evans JR, Mason SL, Foltynie T, Schmand B, De Haan RJ, Post B, Barker RA, Williams-Gray CH. Neurology. 2016 March 15
      Download Publication
    8. Hypothalamic volume loss is associated with reduced melatonin output in Parkinson’s disease. Breen DP, Nombela C, Vuono R, Jones PS, Fisher K, Burn DJ, Brooks DJ, Reddy AB, Rowe JB, Barker RA. Mov Disord. 2016 March 12
      Download Publication
    9. Deletions at 22q11.2 in idiopathic Parkinson’s disease: a combined analysis of genome-wide association data. Mok KY, Sheerin U, Simon-Sanchez J, Salaka A, Chester L et al.  Lancet Neurol. 2016 March 23
      Download Publication
    10. Variation in recent onset Parkinson’s Disease: implications for prodromal detection. Swallow DM, Lawton MA, Grosset KA, Malek N, Smith CR, Bajaj NP, Barker RA et al. J Parkinsons Dis. 2016 March 19
      Download Publication
    11. Serum immune markers and disease progression in an incident Parkinson’s disease cohort (ICICLE-PD). Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans JR et al. Mov Disord. 2016 March 21
      Download Publication
    12. Advancing pharmacotherapy for treating Huntington’s disease: a review of the existing literature. Mason SL, Barker RA. Expert Opin Pharmacother. 2016 Jan
      Download Publication
    13. Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson’s disease with clinical and neuroimaging measures. Ye Z, Rae CL, Nombela C, Ham T, Rittman T, Jones PS, Rodriguez et al. Hum Brain Mapp. 2016 Mar
      Download Publication
    14. Development and external validation of a prognostic model in newly diagnosed Parkinson disease. Velseboer DC, de Bie RM, Wieske L, Evans JR, Mason SL et al. Neurology 2016 Mar Download Publication
    15. Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson’s disease. Zhang J, Rittman T, Nombela C, Fois A, Coyle-Gilchrist I, Barker RA, Hughes LE, Rowe JB. Brain 2016 Jan
      Download Publication
    16. Are stem cell-based therapies for Parkinson’s Disease ready for clinic in 2016? Barker RA, Parmar M, Kirkeby A, Bjorklund A, Thompson L, Brundin P. Journal of Parkinson’s Disease 2016 March
      Download Publication
    17. A new biomarker for Parkinson’s disease? (commentary). Williams-Gray CH. Mov Disord. 2016 Jan
      Download Publication
    18. Comparative epidemiology of incident Parkinson’s disease in Cambridgeshire, UK. Evans JR, Cummins G, Breen DP, Foltynie T, Mason SL, Brayne CE, Williams-Gray CH, Barker RA. J Neurol Neurosurg Psychiatry. 2016 Jan
      Download Publication
    19. The spectrum of clinical features seen with alpha synuclein pathology. Barker RA, Williams-Gray CH. Neuropathol Appl Neurobiol. 2016 Jan
      Download Publication

      2015

    20. Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson’s Disease? Yarnall AJ, Lawson RA, Duncan GW, Breen DP, Khoo TK, Brooks D, Barker RA, Taylor JP, Burn DJ. J Parkinsons Dis. 2015 Oct 2
      Download Publication
    21. Tracking Parkinson’s: Study Design and Baseline Patient Data. Malek N, Swallow DM, Grosset KA, Lawton MA, Marrinan SL, Lehn AC, Bresner C, Bajaj N, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Hardy J, Morris HR, Williams NM, Wood N, Grosset DG. J Parkinsons Dis. 2015 Oct 31
      Download Publication
    22. Olfaction in Parkin single and compound heterozygotes in a cohort of young onset Parkinson’s disease patients. Malek N, Swallow DM, Grosset KA, Lawton MA, Smith CR, Bajaj NP, Barker RA, Ben-Shlomo Y, Bresner C, Burn DJ, Foltynie T, Morris HR, Williams N, Wood NW, Grosset DG, PRoBaNd Investigators. Acta Neurol Scand. 2015 Dec
      Download Publication
    23. Characterization and Visualization of Vesicles in the Endo-Lysosomal Pathway with Surface-Enhanced Raman Spectroscopy and Chemometrics. Huefner A, Kuan WL, Müller KH, Skepper JN, Barker RA, Mahajan S. ACS Nano. 2015 Dec 18
      Download Publication
    24. A simple assessment model to quantifying the dynamic hippocampal neurogenic process in the adult mammalian brain. Choi ML, Begeti F, Barker RA, Kim N. Hippocampus. 2015 Oct 7
      Download Publication
    25. Sleep, but no metabolic, deficits in pre-manifest huntington’s disease. Lazar AS, Panin F, Goodman AO, Lazic SE, Lazar ZI, Mason SL, Rogers L, Murgatroyd PR, Watson L, Singh P, Borowsky B, Shneerson JM, Barker RA. Ann Neurol. 2015 Jul 29.
      Download Publication
    26. Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson’s disease? Duncan GW, Firbank MJ, Yarnall AJ, Khoo TK, Brooks DJ, Barker RA, Burn DJ, O’Brien JT. Mov Disord. 2015
      Download Publication
    27. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease: ICICLE-PD study. Mak E, Su L, Williams GB, Firbank MJ, Lawson RA, Yarnall AJ, Duncan GW, Owen AM, Khoo TK, Brooks DJ, Rowe JB, Barker RA, Burn DJ, O’Brien JT. Brain. 2015 Jul
      Download Publication
    28. Dopamine and Huntington’s disease. Schwab LC, Garas SN, Drouin-Ouellet J, Mason SL, Stott SR, Barker RA. Expert Rev Neurother. 2015 Mar 16:1-14
      Download Publication
    29. Performance of the 12-item WHODAS 2.0 in prodromal Huntington disease. Kim JI, Long JD, Mills JA, Downing N, Williams JK, Paulsen JS; the PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Eur J Hum Genet. 2015 Mar 4. doi: 10.1038
      Download Publication
    30. Winder-Rhodes SE, Hampshire A, Rowe JB, Peele JE, Robbins TW, Owen AM, Barker RA. (2015). Association between MAPT haplotype and memory function in patients with Parkinson’s disease and healthy aging individuals. Neurobio Aging. 36: 1519-28.
      Download Publication
    31. Poole E, Kuan WL, Barker R, Sinclair J. (2015). The human cytomegalovirus non-coding Beta2.7 RNA as a novel therapeutic for Parkinson’s disease – Translational research with no translation.Virus Res. May 21. pii: S0168-1702(15)00178-1. [Epub ahead of print].
      Download Publication
    32. Cruickshank TM, Thompson JA, Dominguez D JF, Reyes AP, Bynevelt M, Georgiou-Karistianis N, Barker RA, Ziman MR. (2015). The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington’s disease: an exploratory study. Brain Behav. [Epub ahead of print].
      Download Publication
    33. Loftus AM, Bucks RS, Thomas M, Kane R, Timms C, Barker RA, Gasson N. (2015). Retrospective assessment of movement disorder society criteria for mild cognitive impairment in Parkinson’s disease. J Int Neuropsychol. 21:137-45.
      Download Publication
    34. Mason SL, Zhang J, Begeti F, Guzman NV, Lazar AS, Rowe JB, Barker RA, Hampshire A. (2015). The role of the amygdala during emotional processing in Huntington’s disease: From pre-manifest to late stage disease. Neuropsychologia. 17: 70: 80-89.
      Download Publication
    35. Drouin-Ouellet J, Sawiak SJ, Cisbani G, Lagace M, Kuan WL, Saint-Pierre M, Dury RJ, Alata W, St-Amour I, Mason SL, Calon F, Lacroix S, Gowland PA, Francis ST, Barker RA, Cicchetti F. (2015). Cerebrovascular and blood-brain barrier impairments in Huntington’s disease: Potential implications for its pathophysiology. Ann Neurol. [Epub ahead of print].
      Download Publication
    36. Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe J. (2015). Improving repsoinse inhibition in Parkinson’s disease with atomoxetine. Biol Psychiatry. Apr 15; 77(8): 740-8.
      Download Publication
    37. Thomas MG, Welch C, Stone L, Allan P, Barker RA, White RB. (2015) PAX6 expression may be protective against dopaminergic cell loss in Parkinson’s disease. CNS Neurol Disord Drug Targets. Aug 20. [Epub ahead of print]
    38. Mason SL, Barker RA. (2015) Rating Apathy in Huntington’s disease: Patients and Companion’s agree. J Huntington’s Dis. 4(1): 49-59.
      Download Publication
    39. Gallo V1, Brayne C, Forsgren L, Barker RA, Petersson J, Hansson O, Lindqvist D, Ruffmann C, Ishihara L, Luben R, Arriola L, Bergareche A, Gavrila D, Erro ME, Vanacore N, Sacerdote C, Bueno-de-Mesquita B, Vermeulen R, Seelen M, Sieri S, Masala G, Ramat S, Kyrozis A, Thricopolou A, Panico S, Mattiello A, Kaaks R, Teucher B, Katzke V, Kloss M, Curry L, Calboli F, Riboli E, Vineis P, Middleton L. (2015) Parkinson’s disease case ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study. Neurodegener Dis. Sep 17. [Epub ahead of print]
    40. Tedroff J, Waters S, Barker RA, Roos R, Squitieri F. (2015) Antidopaminergic medication is associated with more rapidly progressive Huntington’s disease. J Huntington’s Dis. Jul 1;4 (2): 131-40.
      Download Publication
    41. 5. Collins LM, Begeti F, Panin F, Lazar AS, Cruickshank T, Zinman M, Mason SL, Barker RA. (2015) Novel Nut and Bolt task quantifies motor deficits in premanifest and manifest Huntington’s disease. PLoS Curr. Spe 8;7.
    42. Aresnault D, Drouin-Ouellet J, Saint-Pierre M, Petrou P, Dubois M, Kriz J, Barker RA, Cicchetti A, Cicchetti F. (2015). A novel combinational approach of microstimulation and bioluminescence imaging to study the mechanisms of action of cerebral electrical stimulation in mice. J Physiol. May 15; 593 (10): 2257-78.
      Download Publication
    43. Mason SL, Barker RA. (2015). Progress in Huntington’s disease: the search for markers of disease onset and progression. J Neurol. Mar 21.
      Download Publication
    44. Vuono R, Winder-Rhodes S, de Silva R, Cisbani G, Drouin-Ouellet J, REGISTRY Investigators of the European Huntington’s Disease Network, Spillantini MG, Cicchetti F, Barker RA. (2015). The role of tau in the pathological process and clinical expression of Huntington’s disease. Brain. Jul;138: 1907-18.
      Download Publication
    45. Cox TM, Rosenbloom BE, Barker RA. (2015). Gaucher disease and comorbidities: B-cell malignancy and parkinsonism. Am J Hematol. Jul;90 Suppl 1:S25-8.
      Download Publication

      2014

    46. Goldman JG,diseases. Mov Disord 2014;29(5):608-621.
      Download Publication
    47. Barker RA,Journal of Parkinson’s disease 2014;4(4):651-656.
      Download Publication
    48. Duncan GW, Khoo TK, Yarnall AJ, O’Brien JT, Coleman SY, Brooks DJ, Barker RA, Burn DJ (2014). Health-related quality of life in early Parkinson’s disease: The impact of nonmotor symptoms. Mov Disord. 29: 195-202.
      Download Publication
    49. Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Firbank MJ, Nombela C, Winder-Rhodes S, Evans JR, Rowe JB, Mollenhauer B, Kruse N, Hudson G, Chinnery PF, O’Brien JT, Robbins TW, Wesnes K, Brooks DJ, Barker RA, Burn DJ; On behalf of the ICICLE-PD Study Group (2014). Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD Study. Neurology. 82:308-16.
      Download Publication
    50. Duncan GW, Khoo TK, Coleman SY, Brayne C, Yarnall AJ, O’Brien JT, Barker RA, Burn DJ (2014). The incidence of Parkinson’s disease in the North-East of England. Age Ageing. 43:257-63.
      Download Publication
    51. Stott SR, Barker RA (2014). Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson’s disease. Eur J Neurosci. 39:1042-56.
      Download Publication
    52. Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA (2014). Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. Lancet. 383:1138-46.
      Download Publication
    53. Choi ML, Begeti F, Oh JH, Lee SY, O’Keeffe GC, Clelland CD, Tyers P, Cho ZH, Kim YB, Barker RA (2014) Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington’s disease. Neurobiol Dis. 66:19-27.
      Download Publication
    54. Collins LM, Lazic SE, Barker RA (2014) A retrospective analysis of hand tapping as a longitudinal marker of disease progression in Huntington’s disease. BMC Neurol. 14:35.
      Download Publication
    55. Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB (2014) Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease. Brain 137:1145-55.
      Download Publication
    56. Huefner A, Septiadi D, Wilts BD, Patel II, Kuan WL, Fragniere A, Barker RA, Mahajan S (2014). Gold nanoparticles explore cells: Cellular uptake and their use as intracellular probes. Methods. 68:354-63.
      Download Publication
    57. Herva ME, Zibaee S, Fraser G, Barker RA, Goedert M, Spillantini MG (2014). Anti-amyloid compounds inhibit α-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA). J Biol Chem. 289:11897-905.
      Download Publication
    58. Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB (2014) Improving Response Inhibition in Parkinson’s Disease with Atomoxetine. Biol Psychiatry. 137:1145-55
      Download Publication
    59. Kehagia AA, Barker RA, Robbins TW (2014). Revisiting the effects of Parkinson’s disease and frontal lobe lesions on task switching: The role of rule reconfiguration. J Neuropsychol. 8:53-74.
    60. Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, Barker RA (2014). Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 71:589-95.
      Download Publication
    61. Cicchetti F, Lacroix S, Cisbani G, Vallières N, Saint-Pierre M, St-Amour I, Tolouei R, Skepper JN, Hauser RA, Mantovani D, Barker RA, Freeman TB (2014) Mutant
      huntingtin is present in neuronal grafts in huntington disease patients. Ann Neurol. 76:31-42.
      Download Publication
    62. Ali FR, Cheng K, Kirwan P, Metcalfe S, Livesey FJ, Barker RA, Philpott A (2014). The phosphorylation status of Ascl1 is a key determinant of neuronal differentiation and maturation in vivo and in vitro. Development. 141:2216-24.
      Download Publication
    63. Kehagia AA, Housden CR, Regenthal R, Barker RA, Müller U, Rowe J, Sahakian BJ, Robbins TW (2014) Targeting impulsivity in Parkinson’s disease using atomoxetine. Brain 137:1986-97.
      Download Publication
    64. Lawson RA, Yarnall AJ, Duncan GW, Khoo TK, Breen DP, Barker RA, Collerton D, Taylor JP, Burn DJ (2014) Quality of Life and Mild Cognitive Impairment in Early Parkinson’s Disease: Does Subtype Matter? J Parkinsons Dis. [Epub ahead of print].
      Download Publication
    65. Nombela C, Rowe JB, Winder-Rhodes SE, Hampshire A, Owen AM, Breen DP, Duncan GW, Khoo TK, Yarnall AJ, Firbank MJ, Chinnery PF, Robbins TW, O’Brien JT, Brooks DJ, Burn DJ; the ICICLE-PD study group, Barker RA (2014). Genetic impact on cognition and brain function in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain. 137: 2743-58.
      Download Publication
    66. Zhao JW, Dyson SC, Kriegel C, Tyers P, He X, Fahmy TM, Metcalfe SM, Barker RA. (2014) Modelling of a nanotherapeutic “stroma” to deliver LIF, or XAV939, for promotion of human fetal dopaminergic cells in treatment of Parkinson’s disease. Dis Model Mech. 7:1193-203.
      Download Publication
    67. Onorati M, Castigilioni V, Biasci D, Cesana E, Menon R, Vuono R, Talpo F, Goya RL, Lyons PA, Bulfamante GP, Muzio L, Martino G, Toselli M, Farina C, Barker RA, Biella G, Cattaneo E. (2014) Molecular and functional definition of the developing human striatum. Nat Neuroscience. 17:1804-15.
      Download Publication
    68. Moore SF, Guzman NV, Mason SL, Williams-Gray CH, Barker RA. (2014). Which patients with Parkinson’s Disease participate in clinical trials? One centre’s experience with a new cell based therapy trial (TRANSEURO). J Parkinsons Dis. 4:671-6.
      Download Publication
    69. Lawson RA, Yarnell AJ, Duncan GW, Khoo TK, Breen DP, Barker RA, Collerton D, Taylor JP, Burn DJ. (2014). Severity of mild cognitive impairment in early Parkinson’s disease contributes to poorer quality of life. Parkinsonism Relat Disord. 20: 1071-5.
      Download Publication
    70. Kuan WL, Kasis A, Yuan Y, Mason SL, Lazar AS, Barker RA, Goncalves J. (2014). Modelling the natural history of Huntington’s disease progression. J Neurol Neurosurg Psychiatry. 0: 1-7.
      Download Publication
    71. Drouin-Ouellett J, St-Amour I, Saint-Pierrer M, Lamontagne-Proulx J, Kriz J, Barker RA, Cicchetti F. (2014). Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson’s disease. Int J Neuropsychopharmacol. 7: 18
      Download Publication


      2013

    72. Fallon SJ, Williams-Gray CH, Barker RA, Owen AM, Hampshire A (2013). Prefrontal dopamine levels determine the balance between cognitive stability and flexibility. Cerebral Cortex. 23:361-9.
      Download Publication
    73. Hughes LE, Altena E, Barker RA, Rowe JB (2013) Perseveration and Choice in Parkinson’s Disease: The Impact of Progressive Frontostriatal Dysfunction on Action Decisions. Cereb Cortex. 23:1572-81.
      Download Publication
    74. Winder-Rhodes* SE, Evans JR, Ban M, Mason SL, Williams-Gray CH, Foltynie T, Duran R, Mencacci NE, Sawcer SJ, Barker RA (2013). Glucocerebrosidase mutations influence the natural history of Parkinson’s disease in a community-based incident cohort. Brain 136:392-399.
      Download Publication
    75. Thompson JA, Cruikshank TM, Penailillo LE, Lee JW, Newton RU, Barker RA, Ziman MR (2013). The effects of multidisciplinary rehabilitation in patients with early to middle stage Huntington’s Disease: A pilot study. Eur J Neurol. 20:1325-9.
      Download Publication
    76. Carri AD, Onorati M, Lelos MJ, Castiglioni V, Faedo A, Menon R, Camnasio S, Vuono R, Spaiardii P, Talpo F, Toselli M, Martino G, Barker RA, Dunnett SB, Biella G, Cattaneo E (2013). Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation towards authentic DDARP-32 medium sized spiny neurons. Development 140:301-12.
      Download Publication
    77. Cisbani G, Freeman TB, Soulet D, Saint-Pierre M, Gagnon D, Parent M, Hauser RA, Barker RA, Cicchetti F (2013). Striatal allografts in Huntington’s Disease patients; impact of diminished astrocytes and vascularisation on graft viability. Brain 136:433-43.
      Download Publication
    78. Breen DP, Williams-Gray CH, Mason SL, Foltynie T, Barker RA (2013) Excessive daytime sleepiness and its risk factors in incident Parkinson’ Disease. J Neurol Neurosurg Psychiatry 84:233-4.
      Download Publication
    79. Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O’Brien JT, Brooks DJ, Barker RA, Burn DJ (2013). The spectrum of nonmotor symptoms in early Parkinson’s Disease. Neurology 80:276-81.
      Download Publication
    80. Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, Mathur R, Elneil S, Thornton S, Hurrelbrink C, Armstrong RJ, Tyers P, Smith E, Carpenter A, Piccini P, Tai YF, Brooks DJ, Pavese N, Watts C, Pickard JD, Rosser AE, Dunnett SB; the NEST-UK collaboration (2013). The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington’s disease. J Neurol Neurosurg Psychiatry 84:657-65.
      Download Publication
    81. Rittman T, Ghosh BC, McColgan P, Breen DP, Evans J, Williams-Gray CH, Barker RA, Rowe JB (2013). The Addenbrooke’s Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry 84:544-51.
      Download Publication
    82. Nombela C, Rae CL, Grahn JA, Barker RA, Owen AM, Rowe JB (2013). How often does musIc and rhythm improve patients’ perception of motor symptoms in Parkinson’s Disease ? J. Neurol. 260:1404-5.
      Download Publication
    83. Breen DP, Evans JR, Farrell K, Brayne C, Barker RA (2013) Determinants of delayed diagnosis in Parkinson’s disease. J Neurol. 260:1978-81.
      Download Publication
    84. Ellul MA, Cross J, Barker RA (2013) L-dopa responsive parkinsonism secondary to a subdural haematoma. J Clin Neurosci. 20:1022-4.
      Download Publication
    85. Huefner A, Kuan WL, Barker RA, Mahajan S (2013). Intracellular SERS Nanoprobes For Distinction Of Different Neuronal Cell Types. Nano Lett. 13:2463-70.
      Download Publication
    86. Hudson G, Nalls M, Evans JR, Breen DP, Winder-Rhodes S, Morrison KE, Morris HR, Williams-Gray CH, Barker RA, Singleton AB, Hardy J, Wood NE, Burn DJ, Chinnery PF (2013). Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology 80:2042-2048.
      Download Publication
    87. Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, Barker RA (2013) The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 84:1258-64.
      Download Publication
    88. Fallon SJ, Hampshire A, Williams-Gray CH, Barker RA, Owen AM (2013). Putative cortical dopamine levels affect cortical recruitment during planning. Neuropsychologia. 51:2194-201.
      Download Publication
    89. Begeti F, Tan AY, Cummins GA, Collins LM, Guzman NV, Mason SL, Barker RA (2013) The Addenbrooke’s Cognitive Examination-Revised accurately detects cognitive decline in Huntington’s disease. J Neurol. 260:2777-85.
      Download Publication
    90. Whitworth SR, Loftus AM, Skinner TC, Gasson N, Barker RA, Bucks RS, Thomas MG (2013). Personality affects aspects of health-related quality of life in Parkinson’s disease via psychological coping strategies..J Parkinsons Dis. 3:45-53.
      Download Publication
    91. Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK (2013). Linked clinical trials–the development of new clinical learning studies in Parkinson’s disease using screening of multiple prospective new treatments. J Parkinsons Dis. 3:231-9.
      Download Publication
    92. Antoniades CA, Xu Z, Carpenter RH, Barker RA (2013) The Relationship between Abnormalities of Saccadic and Manual Response Times in Parkinson’s Disease. J Parkinsons Dis. 3:557-63.
      Download Publication


      2012

    93. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CA, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M (2012) Diagnostic criteria for Mild Cognitive Impairment in Parkinson’s disease: Movement Disorder Society task Force guidelines. Mov.Disorders. 27:349-56.
      Download Publication
    94. Charlesworth G, Gandhi S, Bras JM, Barker RA, Burn DJ, Chinnery PF, Gentleman SM, Guerreiro R, Hardy J, Holton JL, Lees A, Morrison K, Sheerin UM, Williams N, Morris H, Revesz T, Wood NW (2012). Tau acts as an independent genetic risk factor in pathologically proven PD. Neurobiol Aging. 33:838.e7-11.
      Download Publication
    95. Antoniades CA, Buttery P, FitzGerald JJ, Barker RA, Carpenter RH, Watts C (2012). Deep brain stimulation: eye movements reveal anomalous effects of electrode placement and stimulation. PLoS One. 7:e32830.
      Download Publication
    96. Robertson L, Santini H, O’Donovan KL, Squitieri F, Barker RA, Rakowicz M, Landwehrmeyer GB, Quarrell O (2012). Current Pharmacological Management in Juvenile Huntington’s Disease. Version 3. PLoS Curr. Feb 15 [revised 2012 Mar 26];4:RRN1304.
    97. Höglinger GU, Barker RA, Hagg T, Arias-Carrión O, Caldwell MA, Hirsch EC (2012). Quantitative evaluation of the human subventricular zone. Brain. 135:e221.
      Download Publication
    98. Rae CL, Correia MM, Altena E, Hughes LE, Barker RA, Rowe JB (2012). White matter pathology in Parkinson’s disease: The effect of imaging protocol differences and relevance to executive function. Neuroimage. 62:1675-84.
      Download Publication
    99. Wu K, O’Keefe, Politis M, O’Keeffe GC, Robbins TW, Bose SK, Brooks DJ, Piccini P, Barker RA (2012). The catechol-O-methyltransferase Val 158Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson’s Disease; a PET study. Brain. 135:2449-57.
      Download Publication
    100. Kuan W-L, Poole E, Fletcher M, Karniely S, Tyers P, Wills M, Barker RA*, Sinclair JH* (2012) A novel neuroprotective therapy for Parkinson’s disease using a viral non-coding RNA that protects mitochondrial Complex I activity. J Exp Med. 2091-10 (*equal last author).
      Download Publication
    101. McColgan P, Evans JR, Breen DP, Mason SL, Barker RA, Williams-Gray CH (2012). Addenbrooke’s Cognitive Examination –Revised for mild cognitive impairment in Parkinson’s Disease. Mov.Disorders. 27:1173-7.
    102. Winder-Rhodes S, Garcia-Reitbock P, Ban M, Evans JR, Jacques TS, Kemp[inen A, Foltynie T, Williams-Gray CH, Chinnery PF, Hudson G, Burn DJ, Allcock LM, Sawcer SJ, Barker RA*, Spillantini MG* (2012) Genetics and pathological links between Parkinson’s Disease and the lysosomal disorder Sanfilippo Syndrome. Mov Disord. 27:312-5.[* Equal senior authors].
      Download Publication
    103. Ribeiro D, Laguna Goya R, Ravindran G, Vuono R, Parish CL, Foldi C, Piroth T, Yang S, Parmar M, Nikkhah G, Hjerling-Leffler J, Lindvall O, Barker RA, Arenas E (2012). Efficient expansion and dopaminergic differentiation of human fetal ventral midbrain neural stem cells by midbrain morphogens. Neurobiol Dis. 49C:118-127.
      Download Publication
    104. Kilarski LL, Pearson JP, Newsway V, Majounie E, Knipe MD, Misbahuddin A, Chinnery PF, Burn DJ, Clarke CE, Marion MH, Lewthwaite AJ, Nicholl DJ, Wood NW, Morrison KE, Williams-Gray CH, Evans JR, Sawcer SJ, Barker RA, Wickremaratchi MM, Ben-Shlomo Y, Williams NM, Morris HR (2012). Systematic Review and UK-Based Study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson’s disease. Mov Disord. 27:1522-9.
      Download Publication


      2011

    105. Goodman AO, Rogers L, Pilsworth S, McAllister CJ, Shneerson JM, Morton AJ, Barker RA (2011) . Asymptomatic Sleep Abnormalities Are a Common Early Feature in Patients with Huntington’s Disease.Curr Neurol Neurosci Rep. 11:211-7.
      Download Publication
    106. Cordero-Llana O, Scott SA, Maslen SL, Anderson JM, Boyle J, Chowhdury RR, Tyers P, Barker RA, Kelly CM, Rosser AE, Stephens E, Chandran S, Caldwell MA (2011) Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cells. Cell Death Differ. 18:907-13.
      Download Publication
    107. Decressac M, Wright B, David B, Tyers P, Jaber M, Barker RA, Gaillard A. (2011) Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis. Hippocampus. 21:233-8.
      Download Publication
    108. De Wit S, Barker RA, Dickinson A, Cools R (2011) Habitual versus goal directed action control in Parkinson’s Disease. J Cogn Neurosci. 23:1218-29.
      Download Publication
    109. Bucks RS, Cruise KE, Skinner TC, Loftus AM, Barker RA, Thomas MG (2011) Coping processes and health-related quality of life in Parkinson’s disease. Int J Geriatr Psychiatry. 26:247-55.
      Download Publication
    110. Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, Tabrizi SJ, Barker RA, Piccini P (2011) Microglial activation in regions related to cognitive function predicts disease onset in Huntington’s disease: A multimodal imaging study. Hum Brain Mapp. 32:258-70.
      Download Publication
    111. Pernecsky R, Ghosh BCP, Hughes L, Carpenter RHS, Barker RA, Rowe JB (2011) Saccadic latency in Parkinson’s disease correlates with executive function and brain atrophy, but not motor severity. Neurobiol.Dis. 43:79-85.
      Download Publication
    112. International Parkinsons Disease Genomics Consortium (2011) Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome wide association studies. Lancet 277:641-649.
    113. Goodman AO, Barker RA (2011) Body composition in premanifest Huntington’s disease reveals lower bone density compared to controls. PLoS Curr. Feb 28:3:RRN1214.
    114. Evans JR, Mason SL, Williams-Gray CH, Foltynie T, Trotter M, Barker RA (2011) the factor structure of the UPDRS as an index of disease progression in Parkinson’s disease. J.Park.Dis. 21:1-8.
      Download Publication
    115. The UK Parkinson’s Disease Consortium and The Wellcome Trust Case Control Consortium 2 (2011) Dissection of the genetics of Parkinson’s disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet. 20:345-53.
      Download Publication
    116. Laguna Goya R, Busch R, Mathur R, Coles AJ, Barker RA (2011) Human fetal neural precursor cells can up-regulate MHC class I and class II expression and elicit CD4 and CD8 T cell proliferation. Neurobiol Dis. 41:407-14.
      Download Publication
    117. Nopoulos PC, Aylward EH, Ross CA, Mills JA, Langbehn DR, Johnson HJ, Magnotta VA, Pierson RK, Beglinger LJ, Nance MA, Barker RA, Paulsen JS; the PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2011) Smaller intracranial volume in prodromal Huntington’s disease: evidence for abnormal neurodevelopment.. Brain. 134:137-42.
      Download Publication
    118. Evans JR, Mason SL, Williams-Gray CH, Foltynie T, Brayne C, Robbins TW, Barker RA (2011) The natural history of treated Parkinson’s Disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry. 82:1112-8.
      Download Publication
    119. International Parkinson’s Disease Genomics Consortium (IPDGC); Wellcome Trust Case Control Consortium 2 (WTCCC2) 2011. A two-stage meta-analysis identifies several new loci for Parkinson’s disease.PLoS Genet. 7:e1002142.
      Download Publication
    120. O’Keefe G, Barker RA (2011) Dopamine stimulates EGF release from adult neural precursor cells derived from the subventricular zone via ADAMs. Neuroreport. 22:956-8.
    121. De Yebenes JG, Landwehrmeyer B, Squitieri F, Reilamn R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt A, Tedroff J for the MermaiHD study investigators (2011) Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, placebo-controlled trial. Lancet Neurol. 10:1049-57.
      Download Publication


      2010

    122. Rowe JB, Hughes LE, Barker RA, Owen AM (2010) Dynamic causal modelling of effective connectivity from fMRI: are results reproducible and sensitive to Parkinson’s disease and its treatment? Neuroimage. 2010 Sep;52(3):1015-26. Epub 2010 Jan 4.
      Download Publication
    123. Goya RL, Tyers P, Barker RA (2010). Adult neurogenesis is unaffected by afunctional knock out of MHC class I in mice. Neuroreport. 21:349-53.
    124. Hobbs NZ, Barnes J, Frost C, Henley SMD, Wild EJ, MacDonald K, Barker RA, Scahill RI, Fox NC, Tabrizi SJ (2010). Onset and progression of pathologic atrophy in Huntington Disease: A longitudinal MRi imaging study. AJNR Am J Neuroradiol. 31:1036-41.
      Download Publication
    125. Cools R, Rogers R, Barker RA, Robbins TW (2010) Top-Down Attentional Control in Parkinson’s Disease: Salient Considerations. J Cogn Neurosci. 22:848-59
      Download Publication
    126. Hughes LE, Barker RA, Owen AM, Rowe JB (2010). Parkinson’s disease and healthy aging: Independent and interacting effects on action selection. Hum Brain Mapp. 31:1886-99.
      Download Publication
    127. Rowe JB, Hughes L, Williams-Gray CH, Bishop S, Fallon S, Barker RA, Owen AM (2010) .The val(158)met COMT polymorphism’s effect on atrophy in healthy aging and Parkinson’s disease. Neurobiol Aging. 31:1064-8.
      Download Publication
    128. Wild EJ, Henley SM, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ (2010) Rate and acceleration of whole-brain atrophy in premanifest and early Huntington’s disease. Mov Disord. 25:888-95.
      Download Publication
    129. Saiki M, Baker A, Williams-Gray CH, Foltynie T, Goodman RS, Taylor CJ, Compston DAS, Barker RA, Sawcer SJ, Goris A (2010). Association of the human leucocyte antigen region with susceptibility to Parkinson’s disease. J Neurol Neurosurg Psychiatry. 81:890-1.
      Download Publication
    130. Calder AJ, Keane J, Young AW, Lawrence AD, Mason S, Barker RA (2010) The relation between anger and different forms of disgust: Implications for emotion recognition impairments in Huntington’s Disease. Neuropsychologia. 48:2719-29.
      Download Publication
    131. Antoniades CA, Xu Z, Mason SL, Carpenter RH, Barker RA (2010) Huntington’s disease: changes in saccades and hand-tapping over 3 years.. J .Neurol. 257:1890-8.
      Download Publication
    132. Taylor PL, Barker RA, Blume KG, Cattaneo E, Colman A, Deng H, Edgar H, Fox IJ, Gerstle C, Goldstein LS, High KA, Lyall A, Parkman R, Pitossi FJ, Prentice ED, Rooke HM, Sipp DA, Srivastava A, Stayn S, Steinberg GK, Wagers AJ, Weissman IL. (2010) Patients Beware: Commercialized Stem Cell Treatments on the Web. Cell Stem Cell. 7:43-49.
      Download Publication
    133. Decressac M, Wright B, Tyers P, Gaillard A, Barker RA (2010) Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington’s Disease. Exp Neurol. 226:24-32.
      Download Publication
    134. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen
      JP, Barker RA, Emre M (2010) Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 75:1062-9.
      Download Publication
    135. Mason SL, Wijeyekoon R, Swain R, Ho A, Smith EL, Sahakian B, Barker RA (2010). Cognitive follow up of a small cohort of Huntington’s disease patients over a 5 year period. PLoS Curr. 2;2. pii: RRN1174.
    136. Paulsen JS, Wang C, Duff K, Barker R, Nance M, Beglinger L, Moser D, Williams JK, Simpson S, Langbehn D, van Kammen DP; PREDICT-HD Investigators of the Huntington Study Group (2010). Challenges assessing clinical endpoints in early Huntington disease. Mov Disord. 25:2595-603.
      Download Publication
    137. Goodman AO, Morton AJ, Barker RA (2010) Identifying sleep disturbances in Huntington’s disease using a simple disease-focused questionnaire. PLoS Curr. 2010 Oct 15;2:RRN1189.


      2009

    138. Kehagia AA, Cools R, Barker RA, Robbins TW (2009) Switching between abstract rules reflects disease severity but not dopaminergic status in Parkinson’s disease. Neuropsychologia 47:1117-27.
      Download Publication
    139. Thomas M, Tyers P, Lazic SE, Barker RA, Beazley L, Ziman M (2009) Graft outcomes influenced by co-expression of Pax7 in graft and host tissue. J.Anat. 214:396-405.
      Download Publication
    140. Henley SMD, Wild EJ, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ (2009) Whole-brain atrophy as a measure of progression in premanifest and early huntington’s disease. Mov.Disorders 24:932-6.
    141. Henley SMD, Wild EJ, Hobbs NZ, Scahill RI, Ridgway GR, MacManus DG, Barker RA, Fox NC, Tabrizi SJ (2009) Relationship between CAG repeat length and brain volume in premanifest and early Huntington’s disease. J.Neurol. 256:203-212.
    142. Lewis SJ, Barker RA (2009) Understanding the dopaminergic deficits in Parkinson’s disease: Insights into disease heterogeneity. J Clin Neurosci. 16:620-5.
      Download Publication
    143. O’Keefe G, Tyers P, Aarsland D, Dalley J, Caldwell MA*, Barker RA* (2009)Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proc.Natl.Acad Sci. 106:8754-9 [*joint senior authors].
      Download Publication
    144. Williams-Gray CH, Goris A, Saiki M, Foltynie T, Compston DA, Sawcer SJ, Barker RA (2009). Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease. J Neurol. 256:493-8.
      Download Publication
    145. Lazic SE, Mason SL, Michell AW, Barker RA (2009) Visualising disease progression on multiple variables using vector plots and data plots. BMC Med Res Methodol. 9:32.
      Download Publication
    146. Hobbs N, Wild EJ, Leung KK, Frost C, Barker RA, Scahill RI, Barnes J, Fox NC, Tabrizi SJ (2009). Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington’s disease. NeuroImage 47:1659-65.
      Download Publication
    147. W.Phillips, AW Michell, H Pruess, RA Barker (2009). Animal Models of neurodegenerative diseases. Methods Mol Biol. 549:137-55.
    148. Clelland CD, Choi M, Romberg C, Clemenson GD Jr, Fragniere A, Tyers P, Jessberger S, Saksida LM, Barker RA*, Gage FH*, Bussey TJ (2009). A functional role for adult hippocampal neurogenesis in spatial pattern separation. Science 325;210-213. [*joint senior authors].
      Download Publication
    149. O’Keefe G, Caldwell MA*, Barker RA* (2009) Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain. Cell Cycle 8:2888-94.
    150. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA (2009). The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 132:2958-69.
      Download Publication